Agnes Vitry

Agnes Vitry serves as a Senior Lecturer at the School of Pharmacy, University of South Australia, where she maintains dual appointments as both academic faculty and Senior Research Fellow at the Quality Use of Medicines and Pharmacy Research Centre. Her professional affiliations include significant involvement with Health Action International and Healthy Skepticism, organizations focused on pharmaceutical policy reform.

Her educational background demonstrates deep expertise in pharmaceutical sciences, with a Bachelor of Pharmacy (1980), PhD in Pharmaceutical Sciences (1984), and Master's in Economy and Management of Health Systems (1995), all from prestigious French institutions (University Paris XI and University Paris I).

Vitry's research focuses on critical analysis of pharmaceutical practices, particularly examining quality use of medicines through multiple lenses including pharmaco-epidemiological studies, evaluation of health information quality for professionals and consumers, assessment of drug promotion impact, and medicines policy frameworks. Her work consistently challenges industry practices that prioritize commercial interests over patient outcomes.

Analysis of her publication record reveals strong thematic consistency in investigating methodological flaws in clinical trials, particularly regarding cancer drugs and insulin analogues. She demonstrates particular expertise in identifying how surrogate endpoints in trials may not correlate with actual patient survival benefits, and how post-marketing studies can function as disguised marketing tools rather than genuine scientific inquiry.

• Active member of Health Action International
• Contributor to Healthy Skepticism organization
• Specialist in pharmaceutical policy analysis
• Expert in clinical trial methodology critique

Vitry maintains active research supervision opportunities and welcomes media requests, speaking engagements, and research collaborations, indicating ongoing professional engagement. Her work directly impacts pharmaceutical policy discussions in Australia and internationally, particularly regarding evidence standards for drug approval and cost-effectiveness in healthcare systems.